Saquib jalil

Dr. Saquib jalil

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FSFurqan Ahmad Saddique
Furqan Ahmad Saddique
SZSumera Zaib
Sumera Zaib
SJSaquib jalil
Saquib jalil
SASana Aslam
Sana Aslam
MAMatloob Ahmad
Matloob Ahmad
JIJamshed Iqbal
Jamshed Iqbal

1 November 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MEMohammed El-Gamal
Mohammed El-Gamal
SUSaif Ullah
Saif Ullah
SZSeyed Omar Zareei
Seyed Omar Zareei
SJSaquib jalil
Saquib jalil
SZSumera Zaib
Sumera Zaib
JIJamshed Iqbal
Jamshed Iqbal

1 October 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SAShakeel Ahmad
Shakeel Ahmad
SZSumera Zaib
Sumera Zaib
SJSaquib jalil
Saquib jalil
MSMuhammad Shafiq
Muhammad Shafiq
MAMatloob Ahmad
Matloob Ahmad
JIJamshed Iqbal
Jamshed Iqbal

1 October 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SQSyeda Uroos Qazi
Syeda Uroos Qazi
ANasia naz
asia naz
AHAbdul Hameed
Abdul Hameed
FOFaisal Abdulrhman Osra
Faisal Abdulrhman Osra
SJSaquib jalil
Saquib jalil
AMAgha Zeeshan Mirza
Agha Zeeshan Mirza

1 January 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MKMaria Saleem Khan
Maria Saleem Khan
MNM. ASIF Nawaz
M. ASIF Nawaz
SJSaquib jalil
Saquib jalil
FRFaisal Rashid
Faisal Rashid
AHAbdul Hameed
Abdul Hameed
MAMariya Al-Rashida
Mariya Al-Rashida

14 March 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
SJSaquib jalil
Saquib jalil
ZHZahid Hussain
Zahid Hussain
SASyed Mobashir Ali Abid
Syed Mobashir Ali Abid
AHAbdul Hameed
Abdul Hameed
JIJamshed Iqbal
Jamshed Iqbal
Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder with multiple enzymes involved. In the treatment of AD, multifunctional agents targeting cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors have shown promising results. Herein, a series of novel quinoline–sulfonamides (a1–18) were designed and synthesized as a dual inhibitor of MAOs and ChEs. The in vitro results showed that compounds a5, a12, a11, and a6 exhibited the most potent compounds against specific enzymes. They had IC50 value 0.59 ± 0.04 for MAO-A, 0.47 ± 0.03 for MAO-B, 0.58 ± 0.05 for BChE and 1.10 ± 0.77 for AChE μM respectively. Furthermore, kinetic studies revealed that these compounds are competitive. Molecular docking studies enhanced the understanding of the in silico component, unveiling critical interactions, specifically the hydrogen bonding interaction, π–π, π–alkyl, π–amid and π–sulfur interactions between the ligand and enzymes. These findings suggest that compounds a5, a6, a11, a12, a15, and a18 may be potent multifunctional candidates for AD treatment.